Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | FABP7 | O15540 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11617650 | 1.00 | ALDH1A1 (0.49) | ALDH1A1GAAPKMTMEM97SIGMAR1 | |
| SCHEMBL21416562 | 0.86 | ALDH1A1 (0.46) | ALDH1A1GAAPKMTMEM97SIGMAR1 | |
| SCHEMBL29418686 | 0.84 | ALDH1A1 (0.46) | ALDH1A1GAAPKMSIGMAR1TSHR | |
| SCHEMBL11618583 | 0.83 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL9236592 | 0.83 | ALDH1A1 (0.51) | ALDH1A1GAAPKMTSHRFABP7 | |
| SCHEMBL16837877 | 0.81 | ALDH1A1 (0.46) | ALDH1A1GAAPKMTSHRFABP7 | |
| SCHEMBL32677624 | 0.81 | FABP7 (0.49) | ALDH1A1GAAPKMTMEM97SIGMAR1 | |
| SCHEMBL25910600 | 0.80 | F2 (0.43) | ALDH1A1GAAPKMTMEM97SIGMAR1 | |
| SCHEMBL19749101 | 0.79 | ALDH1A1 (0.52) | ALDH1A1GAATSHRFABP7FABP5 | |
| SCHEMBL29433900 | 0.79 | ALDH1A1 (0.52) | ALDH1A1GAATSHRFABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124317-A2 | Antibody Drug Conjugates | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| US-20250135026-A1 | Antibody Drug Conjugates | BEIGENE SWITZERLAND GMBH (CH) | 2025-05-01 | — | — | US | disclosed |
| CN-118450907-A | Antibody drug conjugates | 百济神州有限公司 | 2024-08-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124317-A2 | Antibody Drug Conjugates | SLC3A2, SLC7A1, SLC43A1 | ALDH1A1 1744/4885GAA 2040/4885PKM 2740/4885 |
| US-20250135026-A1 | Antibody Drug Conjugates | CD22, FCGR2A, FCGR3B | ALDH1A1 403/4885GAA 399/4885PKM 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.